$5980 | Single User
$12980 | Site License
$12980 | Global License

IBD- Market Insights, Epidemiology and Market Forecast 2028
[Published by MIReports]

Published by MIReports: 26 Jul 2019 | 232887 | In Stock

Introduction

Report Summary

"IBD- Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering:

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

IBD Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for IBDin the US, Europe, and Japan are also provided in the report.

IBD Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

IBD Product Profiles & Analysis

This part of the IBD report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

IBD Market Outlook

The IBD market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

IBD Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

IBD Report Insights

Patient Population in IBD

Therapeutic Approaches in IBD

IBD Pipeline Analysis

IBD Market Size and Trends

IBD Market Opportunities

Impact of upcoming Therapies in IBD

IBD Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

IBD Report Assessment

Current Treatment Practices in IBD

Unmet Needs in IBD

Detailed IBD Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the IBD market

Organize sales and marketing efforts by identifying the best opportunities for IBD market

To understand the future market competition in the IBD market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for IBD- Market Insights, Epidemiology and Market Forecast 2028 [Published by MIReports]

  • Table of Contents

    1 Key Insights

    2 IBD Market Overview at a Glance

    2.1 Market Share (%) Distribution of IBD in 2018

    2.2 Market Share (%) Distribution of IBD in 2028

    3 IBD: Disease Background and Overview

    3.1 Introduction

    3.2 Symptoms

    3.3 Etiology

    3.4 Risk Factor

    3.5 Pathophysiology

    3.6 Diagnosis

    3.7 Treatment

    4 Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of IBD in 7MM

    4.3. Total Prevalent Patient Population of IBD in 7MM – By Countries

    5 Epidemiology of IBD by Countries (2016-2028)

    5.1 United States- Epidemiology (2016-2028)

    5.1.1 Assumptions and Rationale

    5.1.2 Prevalent/Incident Cases of IBD in the United States

    5.1.3 Sub-Type Specific cases of IBD in the United States

    5.1.4 Sex- Specific Cases of IBD in the United States

    5.1.5 Diagnosed Cases of IBD in the United States

    5.1.6 Treatable Cases of IBD in the United States

    5.2 EU5 Countries

    5.2.1 Germany

    5.2.1.1 Assumptions and Rationale

    5.2.1.2 Prevalent/Incident Cases of the of IBD in the Germany

    5.2.1.3 Sub-Type Specific cases of IBD in the Germany

    5.2.1.4 Sex- Specific Cases of the IBD in the Germany

    5.2.1.5 Diagnosed Cases of the IBD in the Germany

    5.2.1.6 Treatable Cases of the IBD

    5.2.2 France

    5.2.2.1 Assumptions and Rationale

    5.2.2.2 Prevalent/Incident Cases of the of IBD in the France

    5.2.2.3 Sub-Type Specific cases of IBD in the France

    5.2.2.4 Sex- Specific Cases of the IBD in the France

    5.2.2.5 Diagnosed Cases of the IBD in the France

    5.2.2.6 Treatable Cases of the IBD

    5.2.3 Italy

    5.2.3.1 Assumptions and Rationale

    5.2.3.2 Prevalent/Incident Cases of the of IBD in the Italy

    5.2.3.3 Sub-Type Specific cases of IBD in the Italy

    5.2.3.4 Sex- Specific Cases of the IBD in the Italy

    5.2.3.5 Diagnosed Cases of the IBD in the Italy

    5.2.3.6 Treatable Cases of the IBD

    5.2.4 Spain

    5.2.4.1 Assumptions and Rationale

    5.2.4.2 Prevalent/Incident Cases of the of IBD in the Spain

    5.2.4.3 Sub-Type Specific cases of IBD in the Spain

    5.2.4.4 Sex- Specific Cases of the IBD in the Spain

    5.2.4.5 Diagnosed Cases of the IBD in the Spain

    5.2.4.6 Treatable Cases of the IBD

    5.2.5 United Kingdom

    5.2.5.1 Assumptions and Rationale

    5.2.5.2 Prevalent/Incident Cases of the of IBD in the United Kingdom

    5.2.5.3 Sub-Type Specific cases of IBD in the United Kingdom

    5.2.5.4 Sex- Specific Cases of the IBD in the United Kingdom

    5.2.5.5 Diagnosed Cases of the IBD in the United Kingdom

    5.2.5.6 Treatable Cases of the IBD

    5.3 Japan

    5.3.1 Assumptions and Rationale

    5.3.2 Prevalent/Incident Cases of the of IBD in the Japan

    5.3.3 Sub-Type Specific cases of IBD in the Japan

    5.3.4 Sex- Specific Cases of the IBD in the Japan

    5.3.5 Diagnosed Cases of the IBD in the Japan

    5.3.6 Treatable Cases of the IBD

    6 Current Treatment & Medical practices

    6.1 Treatment Algorithm

    6.2 Treatment Guidelines

    7 Unmet Needs

    8 Marketed Product

    8.1 Drug A: Company 1

    8.1.1 Drug Description

    8.1.2 Mechanism of Action

    8.1.3 Clinical Trials Details

    8.1.4 Advantages & Disadvantages

    8.1.5 Safety and Efficacy

    8.1.6 Product Profile

    8.2 Drug B: Company 2

    8.2.1 Drug Description

    8.2.2 Mechanism of Action

    8.2.3 Clinical Trials Details

    8.2.4 Advantages & Disadvantages

    8.2.5 Safety and Efficacy

    8.2.6 Product Profile

    8.3 Drug C: Company 3

    8.3.1 Drug Description

    8.3.2 Mechanism of Action

    8.3.3 Clinical Trials Details

    8.3.4 Advantages & Disadvantages

    8.3.5 Safety and Efficacy

    8.3.6 Product Profile

    8.4 Drug D: Company 4

    8.4.1 Drug Description

    8.4.2 Mechanism of Action

    8.4.3 Clinical Trials Details

    8.4.4 Advantages & Disadvantages

    8.4.5 Safety and Efficacy

    8.4.6 Product Profile

    8.5 Drug E: Company 5

    8.5.1 Drug Description

    8.5.2 Mechanism of Action

    8.5.3 Clinical Trials Details

    8.5.4 Advantages & Disadvantages

    8.5.5 Safety and Efficacy

    8.5.6 Product Profile

    8.6 : Company 6

    8.6.1 Drug Description

    8.6.2 Mechanism of Action

    8.6.3 Clinical Trials Details

    8.6.4 Advantages & Disadvantages

    8.6.5 Safety and Efficacy

    8.6.6 Product Profile

    8.7 : Company 7

    8.7.1 Drug Description

    8.7.2 Mechanism of Action

    8.7.3 Clinical Trials Details

    8.7.4 Advantages & Disadvantages

    8.7.5 Safety and Efficacy

    8.7.6 Product Profile

    8.8 : Company 8

    8.8.1 Drug Description

    8.8.2 Mechanism of Action

    8.8.3 Clinical Trials Details

    8.8.4 Advantages & Disadvantages

    8.8.5 Safety and Efficacy

    8.8.6 Product Profile

    9 Emerging Drugs

    9.1 Key Cross Competition

    9.2 Emerging company

    9.2.1 Emerging Drug A: Company 12

    9.2.1.1 Other Development Activities

    9.2.1.2 Clinical Development

    9.2.1.3 Clinical Trials Information

    9.2.1.4 Safety and Efficacy

    9.2.1.5 Advantages and Disadvantages

    9.2.1.6 Product Profile

    9.2.2 Emerging Drug B: Company 13

    9.2.2.1 Other Development Activities

    9.2.2.2 Clinical Development

    9.2.2.3 Clinical Trials Information

    9.2.2.4 Safety and Efficacy

    9.2.2.5 Advantages and Disadvantages

    9.2.2.6 Product Profile

    9.2.3 Emerging Drug C: Company 14

    9.2.3.1 Other Development Activities

    9.2.3.2 Clinical Development

    9.2.3.3 Clinical Trials Information

    9.2.3.4 Safety and Efficacy

    9.2.3.5 Advantages and Disadvantages

    9.2.3.6 Product Profile

    9.2.4 Emerging Drug D: Company 15

    9.2.4.1 Other Development Activities

    9.2.4.2 Clinical Development

    9.2.4.3 Clinical Trials Information

    9.2.4.4 Safety and Efficacy

    9.2.4.5 Advantages and Disadvantages

    9.2.4.6 Product Profile

    9.2.5 Emerging Drug E: Company 16

    9.2.5.1 Other Development Activities

    9.2.5.2 Clinical Development

    9.2.5.3 Clinical Trials Information

    9.2.5.4 Safety and Efficacy

    9.2.5.5 Advantages and Disadvantages

    9.2.5.6 Product Profile

    10 7MM Market Analysis

    10.1 7MM Market Size of IBD

    10.2 7MM Percentage Share of Drugs Marketed for IBD

    10.3 7MM Market Sales of IBD by Products

    11 The United States Market Outlook

    11.1 Market Size of IBD in United States

    11.2 Percentage Share of Drugs Marketed for IBD in United States

    11.3 Market Sales of IBD by Products in United States

    11.4 Analysis of Upcoming Therapies and Impact on the Market

    12 EU5 Countries Market Outlook

    12.1 Market Size of IBD in EU5

    12.2 Market Size of IBD in Germany

    12.2.1 Market Size of IBD in Germany

    12.2.2 Percentage Share of Drugs Marketed for IBD in Germany

    12.2.3 Market Sales of IBD by Products in Germany

    12.2.4 Analysis of Upcoming Therapies and Impact on the Market

    12.3 Market Size of IBD in France

    12.3.1 Market Size of IBD in France

    12.3.2 Percentage Share of Drugs Marketed for IBD in France

    12.3.3 Market Sales of IBD by Products in France

    12.3.4 Analysis of Upcoming Therapies and Impact on the Market

    12.4 Market Size of IBD in Italy

    12.4.1 Market Size of IBD in Italy

    12.4.2 Percentage Share of Drugs Marketed for IBD in Italy

    12.4.3 Market Sales of IBD by Products in Italy

    12.4.4 Analysis of Upcoming Therapies and Impact on the Market

    12.5 Market Size of IBD in Spain

    12.5.1 Market Size of IBD in Spain

    12.5.2 Percentage Share of Drugs Marketed for IBD in Spain

    12.5.3 Market Sales of IBD by Products in Spain

    12.5.4 Analysis of Upcoming Therapies and Impact on the Market

    12.6 Market Size of IBD in United Kingdom

    12.6.1 Market Size of IBD in United Kingdom

    12.6.2 Percentage Share of Drugs Marketed for IBD in United Kingdom

    12.6.3 Market Sales of IBD by Products in United Kingdom

    12.6.4 Analysis of Upcoming Therapies and Impact on the Market

    13 The Japan Market Outlook

    13.1 Market Size of IBD in Japan

    13.2 Percentage Share of Drugs Marketed for IBD in Japan

    13.3 Market Sales of IBD by Products in Japan

    13.4 Analysis of Upcoming Therapies and Impact on the Market

    14 Cost Analysis of IBD

    15 Generic Competition in IBD Market

    16 Market Drivers

    17 Market Barriers

    18 Report Methodology

    18.1 Methodology/Research Approach

    18.2 Data Source

    18.2.1 Secondary Sources

    18.2.2 Primary Sources

List Of Tables
in IBD- Market Insights, Epidemiology and Market Forecast 2028 [Published by MIReports]

List of Tables

Table Total Prevalent/Incident Cases of the IBD in 7MM (2016-2028)

Table Total Prevalent/Incident Cases of the IBD in 7MM by Countries (2016-2028)

Table Prevalent/Incident Cases of the IBD in United States (2016-2028)

Table Sub-Type Specific cases of IBD in the United States (2016-2028)

Table Sex- Specific Cases of IBD in the United States (2016-2028)

Table Diagnosed Cases of the IBD in United States (2016-2028)

Table Treatable Cases of the IBD in United States (2016-2028)

Table Prevalent/Incident Cases of the IBD in Germany (2016-2028)

Table Sub-Type Specific cases of IBD in the Germany (2016-2028)

Table Sex- Specific Cases of IBD in the Germany (2016-2028)

Table Diagnosed Cases of the IBD in Germany (2016-2028)

Table Treatable Cases of the IBD in Germany (2016-2028)

Table Prevalent/Incident Cases of the IBD in France (2016-2028)

Table Sub-Type Specific cases of IBD in the France (2016-2028)

Table Sex- Specific Cases of IBD in the France (2016-2028)

Table Diagnosed Cases of the IBD in France (2016-2028)

Table Treatable Cases of the IBD in France (2016-2028)

Table Prevalent/Incident Cases of the IBD in Italy (2016-2028)

Table Sub-Type Specific cases of IBD in the Italy (2016-2028)

Table Sex- Specific Cases of IBD in the Italy (2016-2028)

Table Diagnosed Cases of the IBD in Italy (2016-2028)

Table Treatable Cases of the IBD in Italy (2016-2028)

Table Prevalent/Incident Cases of the IBD in Spain (2016-2028)

Table Sub-Type Specific cases of IBD in the Spain (2016-2028)

Table Sex- Specific Cases of IBD in the Spain (2016-2028)

Table Diagnosed Cases of the IBD in Spain (2016-2028)

Table Treatable Cases of the IBD in Spain (2016-2028)

Table Prevalent/Incident Cases of the IBD in United Kingdom (2016-2028)

Table Sub-Type Specific cases of IBD in the United Kingdom (2016-2028)

Table Sex- Specific Cases of IBD in the United Kingdom (2016-2028)

Table Diagnosed Cases of the IBD in United Kingdom (2016-2028)

Table Treatable Cases of the IBD in United Kingdom (2016-2028)

Table Prevalent/Incident Cases of the IBD in Japan (2016-2028)

Table Sub-Type Specific cases of IBD in the Japan (2016-2028)

Table Sex- Specific Cases of IBD in the Japan (2016-2028)

Table Diagnosed Cases of the IBD in Japan (2016-2028)

Table Treatable Cases of the IBD in Japan (2016-2028)

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Drug Description

Table Mechanism of Action

Table Clinical Trials Details

Table Advantages & Disadvantages

Table Safety and Efficacy

Table Product Profile

Table Comparison of emerging drugs (Immunomodulators) under development

Table Comparison of emerging drugs (other classes) under development

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table Safety and Efficacy

Table Product Advantages and Advantages

Table Clinical Trial Description, 2018

Table7MM- Market Size of IBD in USD MM (2016-2028)

Table 7MM- Market Share IBD by Therapies in USD MM (2016-2028)

Table 7MM- Market Sales of IBD by Therapies in USD MM (2016-2028)

Table US Market Size of IBD in USD, Million (2016-2028)

Table United States-Market Share IBD by Therapies in USD MM (2016-2028)

Table United States-Market Sales of IBD by Therapies in USD MM (2016-2028)

Table EU5 Market Size of IBD (MS) in USD, Million (2016-2028)

Table Germany Market Size of IBD in USD, Million (2016-2028)

Table Germany -Market Share IBD by Therapies in USD MM (2016-2028)

Table Germany -Market Sales of IBD by Therapies in USD MM (2016-2028)

Table France Market Size of IBD in USD, Million (2016-2028)

Table France -Market Share IBD by Therapies in USD MM (2016-2028)

Table France -Market Sales of IBD by Therapies in USD MM (2016-2028)

Table Italy Market Size of IBD in USD, Million (2016-2028)

Table Italy -Market Share IBD by Therapies in USD MM (2016-2028)

Table Italy -Market Sales of IBD by Therapies in USD MM (2016-2028)

Table Spain Market Size of IBD in USD, Million (2016-2028)

Table Spain -Market Share IBD by Therapies in USD MM (2016-2028)

Table Spain -Market Sales of IBD by Therapies in USD MM (2016-2028)

Table United Kingdom Market Size of IBD in USD, Million (2016-2028)

Table United Kingdom -Market Share IBD by Therapies in USD MM (2016-2028)

Table United Kingdom -Market Sales of IBD by Therapies in USD MM (2016-2028)

Table Japan Market Size of IBD in USD, Million (2016-2028)

Table Japan -Market Share IBD by Therapies in USD MM (2016-2028)

Table Japan -Market Sales of IBD by Therapies in USD MM (2016-2028)

Table Market Drivers of IBD

Table Market Barriers of IBD

???

List Of Figures, Charts and Diagrams
in IBD- Market Insights, Epidemiology and Market Forecast 2028 [Published by MIReports]

List of Figures

Figure Market Share (%) Distribution of IBD in 2019

Figure Market Share (%) Distribution of IBD in 2028

Figure Total Prevalent/Incident Cases of the IBD in 7MM

Figure Total Prevalent/Incident Cases of the IBD in 7MM

Figure Prevalent/Incident Cases of the IBD in United States (2016-2028)

Figure Sub-Type Specific cases of the IBD in United States (2016-2028)

Figure Sex- Specific Cases of the IBD in United States (2016-2028)

Figure Diagnosed Cases of the IBD in United States (2016-2028)

Figure Treatable Cases of the IBD in United States (2016-2028)

Figure Prevalent/Incident Cases of the IBD in Germany (2016-2028)

Figure Sub-Type Specific cases of the IBD in Germany (2016-2028)

Figure Sex- Specific Cases of the IBD in Germany (2016-2028)

Figure Diagnosed Cases of the IBD in Germany (2016-2028)

Figure Treatable Cases of the IBD in Germany (2016-2028)

Figure Prevalent/Incident Cases of the IBD in France (2016-2028)

Figure Sub-Type Specific cases of the IBD in France (2016-2028)

Figure Sex- Specific Cases of the IBD in France (2016-2028)

Figure Diagnosed Cases of the IBD in France (2016-2028)

Figure Treatable Cases of the IBD in France (2016-2028)

Figure Prevalent/Incident Cases of the IBD in Italy (2016-2028)

Figure Sub-Type Specific cases of the IBD in Italy (2016-2028)

Figure Sex- Specific Cases of the IBD in Italy (2016-2028)

Figure Diagnosed Cases of the IBD in Italy (2016-2028)

Figure Treatable Cases of the IBD in Italy (2016-2028)

Figure Prevalent/Incident Cases of the IBD in Spain (2016-2028)

Figure Sub-Type Specific cases of the IBD in Spain (2016-2028)

Figure Sex- Specific Cases of the IBD in Spain (2016-2028)

Figure Diagnosed Cases of the IBD in Spain (2016-2028)

Figure Treatable Cases of the IBD in Spain (2016-2028)

Figure Prevalent/Incident Cases of the IBD in United Kingdom (2016-2028)

Figure Sub-Type Specific cases of the IBD in United Kingdom (2016-2028)

Figure Sex- Specific Cases of the IBD in United Kingdom (2016-2028)

Figure Diagnosed Cases of the IBD in United Kingdom (2016-2028)

Figure Treatable Cases of the IBD in United Kingdom (2016-2028)

Figure Prevalent/Incident Cases of the IBD in Japan (2016-2028)

Figure Sub-Type Specific cases of the IBD in Japan (2016-2028)

Figure Sex- Specific Cases of the IBD in Japan (2016-2028)

Figure Diagnosed Cases of the IBD in Japan (2016-2028)

Figure Treatable Cases of the IBD in Japan (2016-2028)

Figure Treatment algorithm for IBD

Figure Diagnosis and Therapy selection

Figure Unmet Needs of IBD Disease

Figure 7MM- Market Size of IBD in USD MM (2016-2028)

Figure 7MM- Market Share IBD by Therapies in USD MM (2016-2028)

Figure US Market Size of IBD in USD, Million (2016-2028)

Figure United States-Market Share IBD by Therapies in USD MM (2016-2028)

Figure United States-Market Sales of IBD by Therapies in USD MM (2017-2028)

Figure EU5 Market Size of IBD (MS) in USD, Million (2016-2028)

Figure Germany Market Size of IBD in USD, Million (2016-2028)

Figure Germany -Market Share IBD by Therapies in USD MM (2016-2028)

Figure Germany -Market Sales of IBD by Therapies in USD MM (2017-2028)

Figure France Market Size of IBD in USD, Million (2016-2028)

Figure France -Market Share IBD by Therapies in USD MM (2016-2028)

Figure France -Market Sales of IBD by Therapies in USD MM (2017-2028)

Figure Italy Market Size of IBD in USD, Million (2016-2028)

Figure Italy -Market Share IBD by Therapies in USD MM (2016-2028)

Figure Italy -Market Sales of IBD by Therapies in USD MM (2017-2028)

Figure Spain Market Size of IBD in USD, Million (2016-2028)

Figure Spain -Market Share IBD by Therapies in USD MM (2016-2028)

Figure Spain -Market Sales of IBD by Therapies in USD MM (2017-2028)

Figure United Kingdom Market Size of IBD in USD, Million (2016-2028)

Figure United Kingdom -Market Share IBD by Therapies in USD MM (2016-2028)

Figure United Kingdom -Market Sales of IBD by Therapies in USD MM (2017-2028)

Figure Japan Market Size of IBD in USD, Million (2016-2028)

Figure Japan -Market Share IBD by Therapies in USD MM (2016-2028)

Additional Details

Publisher

MIReports

Publisher Information

Headquartered in Haidian District, Beijing, MIReports is a global information consulting company, focusing on market data collection and professional analysis.

Reference

232887 |

Number of Pages

146

Report Format

PDF

MIReports Reports

Related Reports

TitleDate PublishedPrice fromMore Details
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,995 More Info
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $10,995 More Info
OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024Summary...
08 Sep 2015 by Global Data USD $9,495 More Info
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $10,995 More Info
Orphan Drug Market Access: Payer Insights on the Present and Future
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
14 Oct 2014 by FirstWord Pharma USD $695 More Info
Payer Insights: Hepatitis C
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
26 Sep 2014 by FirstWord Pharma USD $7,900 More Info
Pharma-Patient Engagement: insights from patient opinion leaders
IntroductionTPatients and Pharma want the same thing, but for different reasons. Patients want acces...
20 Jun 2014 by FirstWord Pharma USD $695 More Info
Inside China’s Pharma Sales Force – insights from the frontline
IntroductionIn 2011, China’s pharmaceutical sales force exceeded that of the U.S. for the first time...
01 Jul 2013 by FirstWord Pharma USD $695 More Info

This report is published by MIReports

Headquartered in Haidian District, Beijing, MIReports is a global information consulting company, focusing on market data collection and professional analysis.

Download Free Report Summary PDF

IBD- Market Insights, Epidemiology and Market Forecast 2028 [Published by MIReports] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)